Sabra Healthcare REIT (SBRA – Research Report), the Real Estate sector company, was revisited by a Wall Street analyst today. Analyst Juan C. Sanabria from BMO Capital maintained a Hold rating on the stock and has a $19.00 price target.
Juan C. Sanabria has given his Hold rating due to a combination of factors related to Sabra Healthcare REIT’s financial performance and strategic positioning. The company reported a strong first quarter with a notable increase in same-store net operating income, although there was a seasonal decline in average occupancy. While the investments year-to-date were modest, Sabra has over $200 million in pending acquisitions, which are expected to yield high returns, and the balance sheet remains strong with a favorable debt-to-EBITDA ratio.
Despite these positive indicators, the company maintained its guidance, which is above street expectations for adjusted funds from operations but did not provide detailed assumptions behind this guidance. Additionally, while the normalized adjusted funds from operations exceeded expectations, the normalized funds from operations per share guidance was slightly below street estimates. These mixed signals contribute to the Hold rating, as there is potential for growth, but also uncertainties that warrant a cautious approach.